Short Interest in InflaRx N.V. (NASDAQ:IFRX) Increases By 28.0%

InflaRx N.V. (NASDAQ:IFRX) saw a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,270,000 shares, an increase of 28.0% from the May 15th total of 992,100 shares. Approximately 2.3% of the shares of the company are short sold. Based on an average trading volume of 467,200 shares, the days-to-cover ratio is currently 2.7 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. 683 Capital Management LLC lifted its holdings in shares of InflaRx by 26.8% in the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after buying an additional 555,000 shares during the period. Woodline Partners LP purchased a new stake in shares of InflaRx in the first quarter valued at approximately $766,000. Northern Trust Corp grew its position in shares of InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock valued at $1,647,000 after purchasing an additional 634,045 shares in the last quarter. Raymond James Financial Inc. purchased a new position in InflaRx in the fourth quarter worth approximately $1,576,000. Finally, DAFNA Capital Management LLC purchased a new position in InflaRx in the first quarter worth approximately $459,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IFRX has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Cantor Fitzgerald began coverage on InflaRx in a research note on Tuesday, April 29th. They set an “overweight” rating and a $10.00 target price on the stock. Guggenheim boosted their target price on InflaRx from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 26th. Oppenheimer reduced their price target on InflaRx from $6.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, May 29th. Finally, Raymond James Financial cut InflaRx from a “strong-buy” rating to an “outperform” rating and set a $2.00 target price on the stock. in a research note on Thursday, May 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, InflaRx currently has an average rating of “Buy” and a consensus target price of $6.60.

InflaRx Price Performance

NASDAQ IFRX opened at $0.80 on Friday. The stock has a market capitalization of $53.57 million, a PE ratio of -0.97 and a beta of 1.29. InflaRx has a 1-year low of $0.71 and a 1-year high of $2.82. The business has a 50 day simple moving average of $1.27 and a two-hundred day simple moving average of $1.70.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. InflaRx had a negative return on equity of 64.17% and a negative net margin of 33,362.70%. On average, analysts anticipate that InflaRx will post -1.04 EPS for the current fiscal year.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.